Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemafibrate + tofogliflozin
- Development stage
- Unknown
- Lead developer
- Kowa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pemafibrate + tofogliflozin is a combination therapy under clinical development by Kowa Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). The combination consists of pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα), and tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This dual-action approach aims to address the complex metabolic and hepatic components of MASH by leveraging pemafibrate's ability to improve lipid metabolism and reduce hepatic inflammation alongside tofogliflozin's glucose-lowering and metabolic benefits. Preclinical studies have demonstrated that the combination significantly alleviates hyperglycemia and hypertriglyceridemia while reducing hepatocyte ballooning, a key histological feature of disease progression.
- Brand names
- K-877-ER + CSG452 combination tablet
- Other names
- Pemafibrate/TofogliflozinPema and Tofo combination
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on pemafibrate + tofogliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemafibrate + tofogliflozin.